Drug Monograph

Drug/Drug Class:	**Lamictal® XR (Lamotrigine) 24 Hour Extended Release Tablet / Anti-seizure Agent**
Prepared for:	MO HealthNet
Prepared by:	ACS, A Xerox Company

☒ **New Criteria** ☐ **Revision of Existing Criteria**

Executive Summary

Purpose:	The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be made available on an open access basis to prescribers, require a clinical edit, or require prior authorization for use.
Dosage Forms:	Each 24 hour extended release tablet of Lamictal® XR contains 250 mg of lamotrigine.
Manufacturer:	GlaxoSmithKline, Research Triangle Park, NC 27709
Indications:	Lamictal® XR 24 hour extended release tablet is indicated for adjunctive therapy for primary generalized tonic-clonic (PGTC) seizures and partial onset seizures with or without secondary generalization in patients ≥ 13 years of age; and conversion to monotherapy in patients ≥ 13 years of age with partial seizures who are receiving treatment with a single antiepileptic drug (AED).
Costs:	$16.82233 per 24 hour extended release tablet of Lamictal® XR Wholesale Acquisition Cost
Summary of Findings:	The Division recommends adding this drug to the current 15 day quantity limitation fiscal edit and to the current psychotropic polypharmacy clinical edit.
Status Recommendation:	☐ Prior Authorization (PA) Required ☐ Open Access ☒ Clinical Edit ☒ Fiscal Edit
Type of PA Criteria:	☐ Increased Risk of ADE ☐ Non-Preferred Agent ☒ Polypharmacy ☒ 15 Day First Fill

Prepared By: Joshua S. Moore, Pharm D.
Date: January 24, 2012

© 2012, ACS, A Xerox Company. All Rights Reserved.